Equifax Q3 revenue, profit rise on mortgage segment growth
Reuters2026/10/20 10:39
Overview
Global data and analytics provider's Q3 revenue grew 10% yr/yr, meeting analyst expectations
Adjusted EPS for Q3 rose 11% and beat analyst expectations
Company returned $158 mln to shareholders via buybacks and dividends
Outlook
Equifax lowers 2026 full-year revenue guidance midpoint to $6.661 bln due to weak U.S. mortgage market
Company expects 2026 adjusted EPS of $8.50, down $0.04 at midpoint from prior guidance
Company maintains 2026 Diversified Markets revenue growth guidance at high single-digit percent
Result Drivers
DIVERSIFIED MARKETS - Co said broad-based growth across business units drove 8% Diversified Markets revenue increase
NEW PRODUCTS - Co attributed record new product Vitality Index of over 17% to innovation in cloud and AI offerings
MORTGAGE REVENUE - Co said U.S. Mortgage revenue grew 15% despite challenging market conditions
Company press release: ID:nPn4SS6j3a
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q3 Revenue |
Meet |
$1.69 bln |
$1.69 bln (18 Analysts) |
Q3 Adjusted EPS |
Beat |
$2.26 |
$2.20 (20 Analysts) |
Q3 EPS |
|
$1.79 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the professional information services peer group is "buy"
Wall Street's median 12-month price target for Equifax Inc. is $194.00, about 22.3% above its October 19 closing price of $158.57
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago
Reuters Recommended Reads
Oct 19 - Zions Bancorp Q3 EPS rises 20% on improved credit quality
Oct 19 - Western Alliance Bancorp Q3 revenue slightly beats estimates, profit rises on wider interest margin
Oct 20 - Commerce Bancshares Q3 EPS beats, helped by loan growth
For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected].
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tom Lee Says Yields Below 5% Mean the AI Selloff Is Nearly Over

Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.
Lycia will issue 17.64 million shares at a price of $18 per share to raise $317.5 million.
Citi is bullish on Palantir (PLTR.US): U.S. government and commercial businesses jointly drive growth, Q3 revenue is expected to exceed expectations again
Citigroup maintains its "Buy" rating on Palantir and raises the target price from $245 to $250.

Despite its stock price being halved, Goldman Sachs maintains a Buy rating: Holding $10 billions in orders, CoreWeave (CRWV) faces a major test with several billions in financing
As a core manufacturer of AI computing power infrastructure, CoreWeave (CRWV.US) holds orders worth tens of billions and its business is expanding rapidly. However, capital expenditure pressure and financing gaps have become the main concerns of the market.
